Results 81 to 90 of about 1,564,380 (249)

Investigating the cell of origin and novel molecular targets in Merkel cell carcinoma: a historic misnomer

Molecular Oncology, EarlyView.
This study indicates that Merkel cell carcinoma (MCC) does not originate from Merkel cells, and identifies gene, protein & cellular expression of immune‐linked and neuroendocrine markers in primary and metastatic Merkel cell carcinoma (MCC) tumor samples, linked to Merkel cell polyomavirus (MCPyV) status, with enrichment of B‐cell and other immune cell
Richie Jeremian, Sriraam Sivachandran, Melissa Galati, Brandon Ramchatesingh, Hibo Rijal, Johnny Hanna, Elena Netchiporouk, May Chergui, Margaret Redpath, Samy Abou Setah, Ivan V. Litvinov   +10 more
wiley   +1 more source

Chloroplast Stromules Function during Innate Immunity [PDF]

, 2015
Jeffrey L. Caplan, Amutha Sampath Kumar, Eunsook Park, Meenu S. Padmanabhan, Kyle Hoban, Shannon Modla, Kirk J. Czymmek, Savithramma P. Dinesh‐Kumar   +7 more
openalex   +1 more source

Multiomic immune clockworks of pregnancy [PDF]

, 2020
Laura S. Peterson, Ina A. Stelzer, Amy S. Tsai, Mohammad Sajjad Ghaemi, Xiaoyuan Han, Kazuo Ando, Virginia D. Winn, Nadine R. Martinez, Kévin Contrepois, Mira N. Moufarrej, Stephen R. Quake, David A. Relman, M Snyder, Gary M. Shaw, David K. Stevenson, Ronald J. Wong, Petra Arck, Martin S. Angst, Nima Aghaeepour, Brice Gaudillière   +19 more
openalex   +1 more source

Gut microbiota diversity is prognostic in metastatic hormone receptor‐positive breast cancer patients receiving chemotherapy and immunotherapy

Molecular Oncology, EarlyView.
In this exploratory study, we investigated the relationship between the gut microbiota and outcome in patients with metastatic hormone receptor‐positive breast cancer, treated in a randomized clinical trial with chemotherapy alone or chemotherapy in combination with immune checkpoint blockade.
Andreas Ullern, Kristian Holm, Nikolai Kragøe Andresen, Andreas Hagen Røssevold, Corinna Bang, Bjørn Naume, Johannes R. Hov, Jon Amund Kyte   +7 more
wiley   +1 more source

Exploiting TCR Repertoire Analysis to Select Therapeutic TCRs for Cancer Immunotherapy

Cells
Over the past decade, numerous innovative immunotherapy strategies have transformed the treatment of cancer and improved the survival of patients unresponsive to conventional chemotherapy and radiation therapy. Immune checkpoint inhibition approaches aim
Ursule M. Demaël, Thunchanok Rirkkrai, Fatma Zehra Okus, Andreas Tiffeau-Mayer, Hans J. Stauss   +4 more
doaj   +1 more source

A bioinformatics screen identifies TCF19 as an aggressiveness‐sustaining gene in prostate cancer

Molecular Oncology, EarlyView.
Gene expression meta‐analysis in multiple prostate cancer patient cohorts identifies Transcription factor 19 (TCF19) as an aggressiveness‐sustaining gene with prognostic potential. TCF19 is a gene repressed by androgen signaling that sustains core cancer‐related processes such as vascular permeability or tumor growth and metastasis.
Amaia Ercilla, Jana R. Crespo, Saioa Garcia‐Longarte, Marta Fidalgo, Sara del Palacio, Natalia Martin‐Martin, Onintza Carlevaris, Ianire Astobiza, Sonia Fernández‐Ruiz, Marc Guiu, Laura Bárcena, Isabel Mendizabal, Ana M. Aransay, Mariona Graupera, Roger R. Gomis, Arkaitz Carracedo   +15 more
wiley   +1 more source

Stability of gene expression by primary bronchial epithelial cells over increasing passage number

BMC Pulmonary Medicine, 2018
Background An increasing number of studies using primary human bronchial epithelial cells (BECs) have reported intrinsic differences in the expression of several genes between cells from asthmatic and non-asthmatic donors.
Stephen R. Reeves, Kaitlyn A. Barrow, Maria P. White, Lucille M. Rich, Maryam Naushab, Jason S. Debley   +5 more
doaj   +1 more source

Immune Monitoring of Trans-endothelial Transport by Kidney-Resident Macrophages [PDF]

, 2016
Efstathios G. Stamatiades, Marie‐Ève Tremblay, Mathieu Bohm, Lucile Crozet, Kanchan Bisht, Daniela Kao, Carolina Coelho, Xiying Fan, William T. Yewdell, Anne Davidson, Peter S. Heeger, Sandra S. Diebold, Falk Nimmerjahn, Frédéric Geissmann   +13 more
openalex   +1 more source

Modeling hepatic fibrosis in TP53 knockout iPSC‐derived human liver organoids

Molecular Oncology, EarlyView.
This study developed iPSC‐derived human liver organoids with TP53 gene knockout to model human liver fibrosis. These organoids showed elevated myofibroblast activation, early disease markers, and advanced fibrotic hallmarks. The use of profibrotic differentiation medium further amplified the fibrotic signature seen in the organoids.
Mustafa Karabicici, Soheil Akbari, Ceyda Caliskan, Canan Celiker, Ozden Oz, Leman Binokay, Gökhan Karakulah, Serif Senturk, Esra Erdal   +8 more
wiley   +1 more source

In vitro properties of patient serum predict clinical outcome after high dose rate brachytherapy of hepatocellular carcinoma

Molecular Oncology, EarlyView.
Following high dose rate brachytherapy (HDR‐BT) for hepatocellular carcinoma (HCC), patients were classified as responders and nonresponders. Post‐therapy serum induced increased BrdU incorporation and Cyclin E expression of Huh7 and HepG2 cells in nonresponders, but decreased levels in responders.
Lukas Salvermoser, Jan Niklas Schäfer, Shraga Nahum Goldberg, Philipp Maximilian Kazmierczak, Moritz Nikolaus Gröper, Philipp Franz Linden, Elif Öcal, Tanja Burkard, Stefanie Corradini, Najib Ben Khaled, Moritz Wildgruber, Max Seidensticker, Jens Ricke, Matthias Stechele, Marianna Alunni‐Fabbroni   +14 more
wiley   +1 more source